NCT06722612View on ClinicalTrials.gov

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

2,916

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER